Presence of oncofetal antigen relatively specific to human pancreatic cancer, designated as pancreatic oncofetal antigen (POA), was first described by Banwo et al in 1974,1 and we have reported high positivity of POA in pancreatic juice of patients with pancreatic cancer by a qualitative assay method of double immunodiffusion or counter electroimmunophoresis. 2 Attention has been focused on the detection of POA for the serological diagnosis of pancreatic cancer. Until now, however, assay of POA has not been used widely because a quantitative assay procedure for POA has not been established.
In this paper we describe a quantitative assay of POA using enzyme Figure 1 . Glass beads coated with rabbit anti-POA were incubated with the samples. Pancreatic oncofetal antigen present in the samples was bound to the glass beads and unbound materials were removed by washing. Subsequently, anti-POA conjugated with peroxidase was incubated with the beads to form anti-POA-peroxidase conjugates on the beads which were then incubated with enzyme substrate to develop a colour which measured the amount of bound anti-POA-peroxidase conjugate. The enzyme reaction was stopped by the addition of sulphuric acid and the intensity of the colour developed was read using a spectrophotometer at 492 nm. A standard curve was obtained by plotting against different concentrations of standard POA. ASSAY PROCEDURE Figure 2 shows an outline of the steps in the POA-enzyme immunoassay. One-tenth millilitre of the serum samples were incubated with antibodycoated glass beads in 0-2 ml of buffer consisting of PBS containing 1% BSA at 37°C for 12 hours. The beads were washed with 0-85% saline solution, and then incubated with 0 3 ml of peroxidase-conjugated anti-POA at 37°C for three hours. After washing, the beads were transferred to Figure 5 shows the standard curve for the enzyme immunoassay of POA, and covers a range from 1 unit/ml to 10 000 unit/ml. Tables 1 and 2 show the reproducibility of the Figure 6 shows the serum POA concentrations in the 169 cases examined. The mean serum POA concentration in the normal controls was 763±51 unit/ml (mean±SEM), and 755±91 unit/ml in patients with benign miscellaneous diseases, 749±87 unit/ml in patients with malignancy other than pancreas, and 784±116 unit/ml in chronic pancreatitis. The serum POA concentration in patients with pancreatic cancer varied from 940-2930 unit/ml with a mean value (±SEM) of 2006 (±122) unit/ml, and was significantly higher than that of other groups (p<0.001, two sample rank test). Abnormal POA concentrations above 1500 unit/ ml accounted for 81% (17/21) of pancreatic cancer, 2% (1/46) of normal controls, 16% (6/37) of benign miscellaneous diseases, 8% (3/37) of malignant miscellaneous diseases and 14% (4/28) of chronic pancreatitis.
REPRODUCIBILITY

CHANGES OF SERUM POA CONCENTRATIONS IN PANCREATIC CANCER
In one resectable pancreatic cancer without metastasis, the serum POA concentration increased from 1610 to 2480 unit/ml with the progress of cancer during one month before operation. After removal of the tumour from the head of the pancreas (35 x25 x20 mm), the POA level fell rapidly to 900 and then to 112 unit/ml after one and two months (Fig. 7) .
Discussion
Oncofetal antigens9 raised in 48% of patients with pancreatic cancer using rocket immunoelectrophoresis assay. A more sensitive assay method is required, however, to detect minute amounts of POA for early diagnosis.
We have developed an enzyme immunoassay22 for POA, which is a safe and sensitive quantitative assaying method with several advantages, as the procedure is simple and radioisotopes are not used.
Reproducibility studies of the established assay gave coefficients of variation of an average of 12 5% for intra-assay, and 12.7% for inter-assay, and the recovery test of the assay showed satisfactory results. These results indicate that the enzyme immunoassay used could be applicable in the preliminary measurement of serum POA concentrations.
Using the enzyme immunoassay, significantly raised serum POA concentrations were observed with a relatively high specificity in patients with pancreatic cancer, compared with those in chronic pancreatitis, other various diseases, or normal controls.
Although there was about 20% false negative rate and 10% false positive, the enzyme immunoassay of POA would be one of the useful aids in detecting the patients with cancer of the pancreas, and the estimation of serum POA could be combined with other morphological examinations such as ultrasonic tomography, computed tomography, endoscopic retrograde cholangio-pancreatography (ERCP), or angiography.
We conclude that POA would be the useful marker of pancreatic cancer, and the enzyme immunoassay of POA would be valuable in the diagnosis of pancreatic cancer. 
